HW252001 NCT07493031 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1

Clinical phase

Not yet recruiting

Recruitment status

98

Planned enrollment

2026-12-11

Primary-completion proxy

Executive view

NCT07493031 evaluates HW252001 in Idiopathic Pulmonary Fibrosis. The disclosed sponsor is Hubei Bio-Pharmaceutical Industrial Technological Institute, the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is The number and severity of treatment emergent adverse events (TEAEs), assessed over up to 11 days.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07493031 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Idiopathic Pulmonary Fibrosis landscape. Drug & Asset MCP drug_fetch was queried for HW252001, while Company & Deal Intelligence MCP organization_fetch was queried for Hubei Bio-Pharmaceutical Industrial Technological Institute.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07493031	HW252001	Phase 1 / Not yet recruiting	Hubei Bio-Pharmaceutical Industrial Technological Institute	China	The number and severity of treatment emergent adverse events (TEAEs) up to 11 days	2026-12-11
NCT07600021	SYH2059	Phase 2 / Not yet recruiting	Sponsor not reported	Geography not reported	Change in FVC from baseline (mL) Week 12	2027-10-30
NCT07593690	HW241045	Phase 1 / Not yet recruiting	Hubei Bio-Pharmaceutical Industrial Technological Institute	China	The number and severity of treatment emergent adverse events (TEAEs) From the first dose administration to 48 hours after the last dose.	2027-01-01
NCT07570888	Nerandomilast	Phase 4 / Not yet recruiting	University of British Columbia	Geography not reported	Determine the persistency of nerandomilast at 4 months when used in combination with mycophenolate in patients with pul… Four months	2027-06-01
NCT07528703	RC-010	Phase 1 / Not yet recruiting	Nanjing Reju Therapeutics Co., Ltd.	China	The incidence of Treatment-emergent adverse events (TEAEs) Day1-Day14	2027-04-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07493031 is a Phase 1, not yet recruiting study with 98 planned participants. Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment.

The primary endpoint is “The number and severity of treatment emergent adverse events (TEAEs)” over “up to 11 days.” The retrieved endpoint description is: To assess the safety and tolerability of HW252001.

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 98 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Idiopathic Pulmonary Fibrosis. These records do not establish direct evidence for NCT07493031 unless the registration number matches.

A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosi…

Phase 2; n=320; Change From Baseline in Forced Vital Capacity at Week 52(Mean) = 38.0 mL (Standard Deviation, NA); Change From Baseline in Forced Vital Capacity at Week 52(Mean) = 176.0 mL (Standard Deviation, NA) Source: https://clinicaltrials.gov/ct2/show/results/NCT06097260

Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial

Phase 2; n=257; FVC(change in) = -110.71 mL ( -148.75 to -70.98); FVC(change in) = -48.42 mL ( -87.66 to -9.04) Source: https://pubmed.ncbi.nlm.nih.gov/42085224/

Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis

Phase 3; n=593; FVC = -136.4 ml ( -172.5 to -104.0); FVC = -49.9 ml ( -79.2 to -19.5) Source: https://pubmed.ncbi.nlm.nih.gov/41812190/

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

No exact Drug & Asset MCP profile was returned for the protocol wording “HW252001.” The report therefore avoids inferring modality, target or global development stage from the name alone.

No exact Company & Deal Intelligence profile was returned for Hubei Bio-Pharmaceutical Industrial Technological Institute. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether HW252001 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07493031
Protocol source: https://clinicaltrials.gov/study/NCT07493031
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.

HW252001 in Idiopathic Pulmonary Fibrosis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes The number and severity of treatment emergent adverse events (TEAEs) and 2026-12-11 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP